Bionano Genomics grants 27,737 stock options

Bionano Genomics reported an insider equity award for its Chief Medical Officer, Alka Chaubey.

Rhea-AI Filing Summary

Bionano Genomics reported an insider equity award for its Chief Medical Officer, Alka Chaubey. On 02/02/2026, Chaubey received a stock option to buy 27,737 shares of common stock at an exercise price of $1.27 per share. The option vests monthly over 48 months, beginning on the one-month anniversary of the vesting commencement date, and becomes fully vested and exercisable on the four-year anniversary of that commencement date. Following this grant, Chaubey beneficially owns 27,737 derivative securities directly, and the filing does not report any share sales.

Insider Trade Summary

Grant/Award: 27,737 shares

Grant/Award 1 txn

Insider Chaubey Alka

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	27,737	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 27,737 contracts (Direct)

Footnotes (1)

1. F1. Each option award vests as follows: the shares subject to the option vest monthly over 48 months beginning on the one-month anniversary of the vesting commencement date, such that the option shall be fully vested and exercisable on the four-year anniversary of the vesting commencement date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Bionano Genomics (BNGO) report for Alka Chaubey?

Bionano Genomics reported a stock option grant to Chief Medical Officer Alka Chaubey. She received options for 27,737 shares of common stock, awarded on 02/02/2026, as part of her equity compensation rather than a purchase or sale of existing shares.

How many Bionano Genomics (BNGO) stock options were granted to the CMO?

The Chief Medical Officer, Alka Chaubey, was granted options for 27,737 shares of Bionano Genomics common stock. These derivative securities give her the right to buy shares in the future at a fixed exercise price if the options become vested and are exercised.

What is the exercise price of the Bionano Genomics (BNGO) options granted?

The granted stock options have an exercise price of $1.27 per share. This means Alka Chaubey can purchase Bionano Genomics common stock at $1.27 per share once the options vest and she chooses to exercise them, regardless of future market price levels.

How do the Bionano Genomics (BNGO) options granted to the CMO vest over time?

The options vest monthly over 48 months, starting on the one-month anniversary of the vesting commencement date. This structure spreads vesting evenly over four years, with the award becoming fully vested and exercisable on the four-year anniversary of that commencement date.

Did the Bionano Genomics (BNGO) Form 4 report any share sales by the CMO?

The Form 4 did not report any stock sales by the Chief Medical Officer. It only disclosed a stock option grant coded as an acquisition of derivative securities, reflecting a new compensation award rather than a disposition of previously held Bionano Genomics shares.

How many derivative securities does the Bionano Genomics (BNGO) CMO own after this grant?

After the reported transaction, Alka Chaubey beneficially owns 27,737 derivative securities in the form of stock options. These options are held directly and represent the full amount from this grant, subject to the vesting schedule described in the filing footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 04:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chaubey Alka

(Last) (First) (Middle)

C/O BIONANO GENOMICS, INC.

9540 TOWNE CENTRE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [ BNGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.27	02/02/2026		A		27,737		(1)	02/01/2036	Common Stock	27,737	$0	27,737	D

Explanation of Responses:

1. Each option award vests as follows: the shares subject to the option vest monthly over 48 months beginning on the one-month anniversary of the vesting commencement date, such that the option shall be fully vested and exercisable on the four-year anniversary of the vesting commencement date.

	/s/ Jonathan V. Dixon, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.